Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-06-09
1996-09-10
Rotman, Alan L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514255, 514256, 514305, 544238, 544332, 544359, 546133, C07D40110, C07D41310, A61K 31495, A61K 3144
Patent
active
055546137
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/GB 93/01165 filed Jun. 02, 1993.
FIELD OF INVENTION
This invention concerns heterocyclic derivatives which are useful in inhibiting squalene synthase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with methods of using such heterocyclic derivatives in treating diseases and medical conditions where inhibition of squalene synthase is desirable, for example in treating diseases or medical conditions such as hypercholesterolemia and atherosclerosis.
BACKGROUND TO INVENTION
Several different classes of compounds have been reported to possess the capability of being able to lower cholesterol levels in blood plasma. For example agents which inhibit the enzyme HMG CoA reductase, which is essential for the production of cholesterol, have been reported to reduce levels of serum cholesterol. Illustrative of this class of compounds is the HMG CoA reductase inhibitor known as lovastatin which is disclosed in U.S. Pat. No. 4,231,938. Other agents which are reported to lower serum cholesterol include those which act by complexing with bile acids in the intestinal system and which are hence termed "bile acid sequestrants". It is believed that many of such agents act by sequestering bile acids within the intestinal tract. This results in a lowering of the levels of bile acid circulating in the enteroheptatic system and promoting replacement of bile acids by synthesis in the liver from cholesterol, which results in an upregulation of the heptatic LDL receptor, and thus in a lowering of circulating blood cholesterol levels.
Squalene synthase is a microsomal enzyme which catalyses the first committed step of cholesterol biosynthesis. Two molecules of farnesyl pyrophosphate (FPP) are condensed in the presence of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) to form squalene. The inhibition of this committed step to cholesterol should leave unhindered biosynthetic pathways to ubiquinone, dolichol and isopentenyl t-RNA. Elevated cholesterol levels are known to be one of the main risk factors for ischaemic cardiovacsular disease. Thus, an agent which inhibits squalene synthase should be useful in treating diseases and medical conditions in which a reduction in the levels of cholesterol is desirable, for example hypercholesterolemia and atherosclerosis.
Thus far, the design of squalene synthase inhibitors has concentrated on the preparation of analogues of the substrate farnesyl pyrophosphate (FPP), and hence on compounds which contain phosphorus groups. For example, the preparation of phosphorous-containing squalene synthase inhibitors is reported in published European Patent Application No. 409,181; and the preparation of isoprenoid (phosphinylmethyl)phosphonates as inhibitors of squalene synthase is reported by Biller et al, J. Med. Chem., 1988, 31, 1869.
Quinuclidine derivatives which inhibit squalene synthase have been reported in U.S. Pat. No. 5,135,935 and WO 92/15579.
DISCLOSURE OF INVENTION
The present invention is based on the discovery that certain heterocyclic derivatives are inhibitors of squalene synthase, and are hence useful in treating diseases and medical conditions in which inhibition of squalene synthase is desirable.
According to the present invention there is provided a compound of formula I (formula set out hereinafter together with the other chemical formulae referred to herein), or a pharmaceutically acceptable salt thereof, wherein: double bond; atoms; more substituents independently selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino N-(1-6C)alkylcarbamoyl, di-N,N-[(1-6C)alkyl]carbamoyl, (1-6C)alkoxycarbonyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, halogeno(1-6C)alkyl, (1-6C)alkanoylamino,(1-4C)alkylenedioxy, (1-6C)alkanoyl and oxime derivatives thereof and 0-(1-6C)alkyl ethers of said oxime derivatives.
It will be understood
REFERENCES:
patent: 3405134 (1968-10-01), Judd
patent: 3534053 (1970-10-01), Sallay et al.
patent: 3586694 (1971-06-01), Shen et al.
patent: 3655675 (1972-04-01), Carabateas
patent: 3679690 (1972-07-01), Carabateas
patent: 3725410 (1973-04-01), Potoski et al.
patent: 3763168 (1973-10-01), Carabateas
patent: 3857848 (1974-12-01), Mauvernay et al.
patent: 4038402 (1977-07-01), Kaminka et al.
patent: 4224332 (1980-09-01), Gueremy et al.
patent: 4599344 (1986-07-01), Morgan
patent: 5135935 (1992-08-01), Alberts et al.
patent: 5242914 (1993-09-01), Kawamoto et al.
patent: 5286864 (1994-02-01), Walther et al.
patent: 5385912 (1995-01-01), Neuenschwander et al.
Rotman Alan L.
Zeneca Limited
LandOfFree
Heterocyclic derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1320596